Clinical trials
Vasculitis clinical trials
Below are recruiting vasculitis clinical trials, each written for real people, not researchers. We’re tracking 101 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02593565Recruiting
Pregnancy blood-vessel disease registry study
This is a pregnancy registry that collects information from people with certain blood-vessel inflammatory diseases during pregnancy. It helps researchers better understand these conditions in pregnancy and may guide future care.
Tampa, FloridaAges 18–50 - NCT03004326Recruiting
Biopsy study to test skin inflammation gene signals
This study uses a skin biopsy to look at “gene signals” (transcriptomics) in patients with active vasculitis that shows up on the skin. It may help researchers understand what is happening in your disease and how different types of vasculitis differ.
Los Angeles, CaliforniaAges 5 years+ - NCT05734404Recruiting
Long-term study of brain vessel inflammation
This study follows adults diagnosed with inflammation of blood vessels in the brain (CNS vasculitis). It aims to better understand the condition over time and could help improve how it’s diagnosed and managed.
Rochester, MinnesotaAges 18 years+ - NCT04629144RecruitingPhase 2
Belimumab for active cryoglobulinemia vasculitis after rituximab
This Phase 2 study tests belimumab (or a placebo) to see if it improves safety and disease control in adults with active cryoglobulinemia vasculitis. You may be eligible if you have had rituximab induction treatment shortly before joining, and your illness is still active.
BloisAges 18 years+ - NCT02939573RecruitingPhase 2
Study of medicines for skin-only vasculitis flares
This Phase 2 trial tests different medicines to calm active skin vasculitis and prevent flare-ups. It’s for people whose vasculitis mainly affects the skin, not major organs like kidneys or the brain.
Kansas City, KansasAges 18 years+ - NCT07595367RecruitingPhase 2
BBD-1 immune therapy for IgA vasculitis
This trial tests a new drug called BBD-1 that may help treat IgA vasculitis, a condition where your immune system attacks small blood vessels, causing a purple rash and organ damage. The study measures how well BBD-1 reduces symptoms and side effects.
Baltimore, MarylandAges Any age - NCT02257866Recruiting
Study of blood vessel inflammation over time
This study looks at different types of blood vessel inflammation (vasculitis) to learn more about why they happen and how they progress. By joining, you may help doctors better understand these conditions and improve future treatments.
Bethesda, MarylandAges 3 years+ - NCT06824714Recruiting
Predicting blood vessel damage in large vessel vasculitis
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
Nanjing, JiangsuAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT07168161RecruitingPhase 3
BDB-001 for ANCA vasculitis (GPA/MPA) trial
This trial tests a new drug called BDB-001 for people with a type of blood vessel inflammation (ANCA vasculitis, specifically GPA or MPA). It aims to see if adding BDB-001 to standard treatment can help control the disease better.
Beijing, Beijing MunicipalityAges 18–75 - NCT06072482RecruitingPhase 4
Avacopan for ANCA vasculitis (GPA or MPA)
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
Anchorage, AlaskaAges 18–100 - NCT02967068Recruiting
Share your study tissue for future research
This study is a “tissue repository” that collects and stores leftover tissue from other approved VCRC studies. If you already took part in one of those studies, you may be able to let researchers use your tissue to help answer future questions.
Boston, MassachusettsAges Any age - NCT04006535Recruiting
Genetic testing study for vasculitis in families and children
This study uses a detailed DNA test to look for possible genetic causes of vasculitis (inflammation of blood vessels) in children and adults. It may help researchers better understand why vasculitis happens, especially in families.
Paris, Île-de-France RegionAges Any age - NCT04413331Recruiting
Study follows adults with vasculitis over time
This observational study follows adults with vasculitis (inflammation of blood vessels) during an active flare or relapse. It aims to better understand how the disease changes over time and may help researchers plan future treatments.
ParisAges 18 years+ - NCT05364892Recruiting
Biobank study for ANCA-associated vasculitis patients
This study collects and stores health information and possibly samples from people diagnosed with ANCA-associated vasculitis to help researchers learn more about the disease. It may help future studies, but it is mainly focused on collection rather than testing a new treatment.
Brest, BrestAges 18–99 - NCT05383339Recruiting
Testing blood markers in autoimmune, vasculitis, and autoinflammation
This study looks at blood “biomarkers,” or measurable body signals, in people with autoimmune diseases, vasculitis, or autoinflammatory conditions. The goal is to better understand these illnesses and how they relate to disease activity.
Paris, FranceAges 18 years+ - NCT05962840RecruitingPhase 4
Rituximab plus telitacicept for ANCA vasculitis
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
BeijingAges 18–65 - NCT05965284RecruitingPhase 4
Telitacicept to help keep ANCA vasculitis in remission
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Beijing, Beijing MunicipalityAges 18–65 - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT06611696RecruitingPhase 4
Avacopan vs lower-dose steroids for new vasculitis
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Toyoake, Aichi-kenAges 18 years+ - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT06794827Recruiting
Early access avacopan for ANCA vasculitis
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
LeidenAges 16 years+ - NCT06887062RecruitingPhase 2
Testing dapagliflozin and bosentan for large vessel vasculitis
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
EdinburghAges 18 years+ - NCT07151521Recruiting
FAPI PET/CT in ANCA vasculitis with lung disease
This study uses a special PET/CT scan (called FAPI) to look at inflammation in people with ANCA-associated vasculitis and interstitial lung disease. It may help doctors see how active the disease is and guide treatment.
ShanghaiAges 18 years+
Hear when a new Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Vasculitis trials by city
Studies with a site in or near these metro areas.
Vasculitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for vasculitis?
- Yes. Clin2 currently lists 101 recruiting vasculitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vasculitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vasculitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.